View More
Learn from expert faculty what key clinical considerations inform the use of biosimilars in oncology practice with this series of ClinicalThought™ commentaries!
How do biosimilars compare with reference biologics and small-molecule compounds? Here’s my take.
Rowena N. Schwartz, PharmD, BCOP
Physicians:
maximum of 0.25 AMA PRA Category 1 Credits™
Registered Nurses:
0.2 Nursing contact hours
Pharmacists:
0.25 contact hours (0.025 CEUs)
Released: November 14, 2018
Expired:
No longer available for credit
Here’s my take on why some of the key reasons biosimilars may be an attractive cost-cutting measure in cancer care also pose a challenge to their widespread adoption.
Gary H. Lyman, MD, MPH, FASCO, FACP, FRCP
Physicians:
maximum of 0.25 AMA PRA Category 1 Credits™
Registered Nurses:
0.2 Nursing contact hours
Pharmacists:
0.25 contact hours (0.025 CEUs)
Released: December 18, 2018
Expired:
No longer available for credit
Herein, I summarize recent biosimilar approvals as well as how these agents might affect patient care and counseling in oncology practice.
Jeffrey Crawford, MD
Physicians:
maximum of 0.25 AMA PRA Category 1 Credits™
Registered Nurses:
0.2 Nursing contact hours
Pharmacists:
0.25 contact hours (0.025 CEUs)
Released: January 18, 2019
Expired:
No longer available for credit
Contact Clinical Care Options
For customer support please email: customersupport@cealliance.com
Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191
You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.